Attention-deficit/Hyperactivity Disorder (ADHD) Market Size and Share Analysis, Key Companies, Emerging Therapies and Epidemiology Forecast

Attention-deficit/hyperactivity disorder (ADHD) is a brain disorder marked by an ongoing pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development. It is a group of behaviors and is also called as attention deficit disorder (ADD). It is a behavioral disorder that includes symptoms such as inattentiveness, hyperactivity, and impulsiveness.

Symptoms of ADHD tend to be noticed at an early age and may become more noticeable when a child’s circumstances change, such as when they start school. Most cases are diagnosed when children are 6 to 12 years old. The symptoms of ADHD usually improve with age, but many adults who were diagnosed with the condition at a young age continue to experience problems. People with ADHD may also have additional problems, such as sleep and anxiety disorders. The exact cause of ADHD is still not known. Like many other illnesses, several factors can contribute to ADHD, such as genes, cigarette smoking, alcohol use, or drug use during pregnancy, exposure to environmental toxins during pregnancy, exposure to environmental toxins, such as high levels of lead, at a young age, low birth weight or brain injuries.

Get a Free Sample Copy of the Report at:

DelveInsight’s “Attention-deficit/Hyperactivity Disorder (ADHD) Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Attention-deficit/Hyperactivity Disorder (ADHD), historical and forecasted epidemiology as well as the Attention-deficit/Hyperactivity Disorder (ADHD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Attention-deficit/Hyperactivity Disorder (ADHD) market report also covers emerging drugs, current treatment practices, Attention-deficit/Hyperactivity Disorder (ADHD) market size and share of the individual therapies, current and forecasted Attention-deficit/Hyperactivity Disorder (ADHD) Market Size from 2017 to 2030 segmented by seven major markets. The report provides a detailed current Attention-deficit/Hyperactivity Disorder (ADHD) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market. 

Attention-deficit/Hyperactivity Disorder (ADHD) Market Key Facts

  • Among the 7MM, the US had the highest number of cases of Attention-deficit/Hyperactivity Disorder (ADHD), followed by Japan and other European countries.
  • Among the European countries, France had the highest diagnosed prevalent population of ADHD with 2,387,148 cases, followed by Italy in 2017. On the other hand, Germany had the lowest diagnosed prevalent population in 2017.
  • Japan was estimated to account for 3,138,319 diagnosed prevalent cases of ADHD in 2017.
  • The Centers for Disease Control and Prevention (CDC) suggests that the estimated number of children diagnosed with ADHD, according to a national 2016 parent survey, were 1 is 6.1 million (9.4%). This number includes 388,000 children aged 2–5 years, 4 million children aged 6–11 years and 3 million children aged 12–17 years. 
  • As per the ADHD Institute, a mean worldwide prevalence of 2.2% (range: 0.1–8.1%) of ADHD has been estimated in children and adolescents (aged <18 years). The mean prevalence of ADHD within Asia, Europe, the Americas, in adults (aged 18–44 years) ranges has been reported as ~2.8% overall (range: 0.6–7.3%).
  • As per a study conducted by Catalá-López et al. titled “Prevalence of attention deficit hyperactivity disorder among children and adolescents in Spain: a systematic review and meta-analysis of epidemiological studies”, the overall pooled-prevalence of ADHD was estimated to be 6.8% (4.9–8.8%), representing 361,580 (260,550–467,927) children and adolescents in the community among 13,026 subjects that were considered for the study.

Key Benefits of Attention-deficit/Hyperactivity Disorder (ADHD) Market Report

  • Attention-deficit/Hyperactivity Disorder (ADHD) market report provides an in-depth analysis of Attention-deficit/Hyperactivity Disorder (ADHD) Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major markets i.e. EU5 (Germany, Italy, Spain, France, and the UK), Japan, and the United States.
  • The report will help in developing business strategies by understanding the Attention-deficit/Hyperactivity Disorder (ADHD) Market trends & developments, key players, and future market competition that will shape and drive the market in the upcoming years.
  • The report covers Attention-deficit/Hyperactivity Disorder (ADHD) market growth and current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
  • The report provides a detailed assessment of the Attention-deficit/Hyperactivity Disorder (ADHD) patient population, market drivers & barriers, Unmet Needs, market opportunities, comparative analysis of pipeline products with detailed clinical profiles, and other factors. 

Attention-deficit/Hyperactivity Disorder (ADHD) Market

Attention-deficit/Hyperactivity Disorder (ADHD) market size is expected to increase during the forecast period owing to the rise in the number of prevalent cases in the 7MM. The launch of upcoming therapies will also boost the market growth.

The Attention-deficit/Hyperactivity Disorder (ADHD) market outlook section of the report helps to build a detailed comprehension of the historic, current and forecasted Attention-deficit/Hyperactivity Disorder (ADHD) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology. 

The report gives a thorough detail of Attention-deficit/Hyperactivity Disorder (ADHD) market trends and shares analysis of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders. 

Attention-deficit/Hyperactivity Disorder (ADHD) Epidemiology

The Attention-deficit/Hyperactivity Disorder (ADHD) epidemiology section covers insights about historical and current Attention-deficit/Hyperactivity Disorder (ADHD) patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030. It helps to recognize the causes of current and forecasted Attention-deficit/Hyperactivity Disorder (ADHD) epidemiology trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Attention-deficit/Hyperactivity Disorder (ADHD) Epidemiology Segmentation – 

  • Total Diagnosed Prevalent Cases
  • Gender-specific Diagnosed Prevalent Cases
  • Gender-specific Diagnosed Prevalent Cases of ADHD in Adults
  • Subtype-specific Diagnosed Prevalent Cases

Attention-deficit/Hyperactivity Disorder (ADHD) Drugs Uptake and Key Market Players

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Attention-deficit/Hyperactivity Disorder (ADHD) market or expected to get launched in the market during the study period. The analysis covers the Attention-deficit/Hyperactivity Disorder (ADHD) market by drug uptake; patient uptake by therapies; and sales of each drug.   

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Attention-deficit/Hyperactivity Disorder (ADHD) Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the Attention-deficit/Hyperactivity Disorder (ADHD) market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for Attention-deficit/Hyperactivity Disorder (ADHD) emerging therapies.

Get a Free Sample Copy of the Report at:

Attention-deficit/Hyperactivity Disorder (ADHD) Companies:

  • Shire
  • KemPharm
  • Tris Pharma
  • Arbor Pharma
  • Neos Therapeutics
  • Highland Therapeutics
  • Rhodes Pharmaceuticals
  • Supernus Pharmaceuticals
  • Otsuka Pharmaceuticals
  • Hisamitsu Pharmaceutical 

And many others.

Attention-deficit/Hyperactivity Disorder (ADHD) Therapies covered in the report include:

  • KP415
  • KP484
  • SPN-812
  • Centanafadine

And many more.

Table of Content

  1. Key Insights
  2. Executive Summary 
  3. Attention-deficit/Hyperactivity Disorder (ADHD) Competitive Intelligence Analysis
  4. Attention-deficit/Hyperactivity Disorder (ADHD) Market Overview at a Glance
  5. Attention-deficit/Hyperactivity Disorder (ADHD) Disease Background and Overview
  6. Attention-deficit/Hyperactivity Disorder (ADHD) Patient Journey
  7. Attention-deficit/Hyperactivity Disorder (ADHD) Epidemiology and Patient Population
  8. Attention-deficit/Hyperactivity Disorder (ADHD) Treatment Algorithm, Current Treatment, and Medical Practices
  9. Attention-deficit/Hyperactivity Disorder (ADHD) Unmet Needs
  10. Key Endpoints of Attention-deficit/Hyperactivity Disorder (ADHD) Treatment
  11. Attention-deficit/Hyperactivity Disorder (ADHD) Marketed Products
  12. Attention-deficit/Hyperactivity Disorder (ADHD) Emerging Therapies
  13. Attention-deficit/Hyperactivity Disorder (ADHD) Seven Major Market Analysis
  14. Attribute Analysis
  15. Attention-deficit/Hyperactivity Disorder (ADHD) Market Outlook (7 major markets)
  16. Attention-deficit/Hyperactivity Disorder (ADHD) Access and Reimbursement Overview
  17. KOL Views on the Attention-deficit/Hyperactivity Disorder (ADHD) Market.
  18. Attention-deficit/Hyperactivity Disorder (ADHD) Market Drivers
  19. Attention-deficit/Hyperactivity Disorder (ADHD) Market Barriers
  20. Appendix
  21. DelveInsight Capabilities
  22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Get a Free Sample Copy of the Report at:

Latest Reports By DelveInsight:

Attention-deficit/hyperactivity disorder (ADHD) Epidemiology Forecast
DelveInsight’s Attention-deficit/hyperactivity disorder (ADHD) – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Attention-deficit/hyperactivity disorder (ADHD) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Attention-deficit/hyperactivity disorder (ADHD) Pipeline Insights
Attention-deficit/hyperactivity disorder (ADHD) Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Attention-deficit/hyperactivity disorder (ADHD) market.

Throat Cancer Market
DelveInsight’s “Throat Cancer Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Throat Cancer market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

Adult Spinal Deformity Market
DelveInsight’s “Adult Spinal Deformity Market Insights, Competitive Landscape and Market Forecast 2026” report delivers an in-depth understanding of Adult Spinal Deformity and the historical and forecasted Adult Spinal Deformity market trends in the US, EU5 (Germany, France, Spain, Italy, and United Kingdom) and Japan.

Latest HealthCare Blogs By DelveInsight:

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Contact Info:
Shruti Thakur
DelveInsight Business Research
Email: [email protected]
Phone No: +91-9650213330
Connect With Us at:
LinkedIn | Facebook | Twitter
Healthcare Blog
Get a Free Sample Copy of the Report at:

Leave a Reply

Your email address will not be published. Required fields are marked *